World Health Organization Raises Concern Over Critical Scarcity of Obesity Jabs

Less than 10% of individuals that would benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it publishes its initial guidance on the medications.

With in excess of 1,000,000,000 people worldwide now living with obesity, it is urging broader and more equitable availability to these injectable treatments.

Based on estimates, over two billion are projected to be obese by 2030 without intervention.

"Our new guidelines affirms that obesity is a lifelong illness that can be managed with holistic and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are key hurdles to universal availability to the injections that can help people shift considerable weight, says the organization.

Weight-Loss Drug Supply Crisis

Even in the present most favorable case, the production of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, as stated by the WHO.

The advice urges governments and firms to expand availability, through approaches including licensing agreements.

Exclusive production rights on a key compound – the main component of a leading brand – is due to expire in several countries in 2026.

How Obesity Injections Operate

These medications replicate a body's own hormone to slow digestion, suppress the appetite and enhance satiety so users consume fewer calories.

People typically see weight reduction within a few weeks of starting on the once-weekly jabs.

Studies suggests patients may regain a significant portion a year later of discontinuing the medication, because their normal food cravings return.

Being above a healthy weight increases your likelihood for experiencing medical conditions, such as diabetes, heart disease, brain attack, and specific malignancies.

Obesity affects individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.